BioXcel Therapeutics Inc BTAI shares are trading higher Wednesday after the company announced that the U.S. Food and Drug Administration approved IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
IGALMI is the first new acute treatment for schizophrenia or bipolar disorder-associated agitation in nearly a decade. It can be self-administrated by patients under the supervision of a healthcare provider.
BioXcel said it expects to launch IGALMI in the U.S. in the second quarter.
BioXcel is a biopharmaceutical company utilizing artificial intelligence approaches to identify and develop transformative medicines in neuroscience and immuno-oncology.
See Also: Why Tilray Brands Stock Is Trading Higher Today
BTAI 52-Week Range: $14.32 - $38.99
The stock was up 16.9% at $23.16 at press time, according to data from Benzinga Pro.
Photo: jarmoluk from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
